Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Bioventus's ebitda for the twelve months ending Sep 26, 2026 was $81.72M, up 17.9% year over year. For fiscal 2025 it was $100.99M, up 193.9% from the year before. The highest annual figure on record is $100.99M in fiscal 2025.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$100.99M	+193.9%
FY2024	Dec 31, 2024	$34.36M	–
FY2023	Dec 31, 2023	-$24.36M	–
FY2022	Dec 31, 2022	-$111.84M	-338.3%
FY2021	Dec 31, 2021	$46.94M	-5.9%
FY2020	Dec 31, 2020	$49.88M	-18.9%
FY2019	Dec 31, 2019	$61.51M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 26, 2026	$10.75M	-15.0%
Q2 FY2026	Jun 27, 2026	$20.17M	+1.8%
Q1 FY2026	Mar 28, 2026	$19.62M	+17.3%
Q4 FY2025	Dec 31, 2025	$31.18M	+55.1%
Q3 FY2025	Sep 27, 2025	$12.65M	+121.5%
Q2 FY2025	Jun 28, 2025	$19.81M	–
Q1 FY2025	Mar 29, 2025	$16.73M	+0.1%
Q4 FY2024	Dec 31, 2024	$20.11M	+47.5%
Q3 FY2024	Sep 28, 2024	$5.71M	+20.6%
Q2 FY2024	Jun 29, 2024	-$29.41M	-425.2%
Q1 FY2024	Mar 30, 2024	$16.71M	–
Q4 FY2023	Dec 31, 2023	$13.63M	+944.4%
Q3 FY2023	Sep 30, 2023	$4.74M	–
Q2 FY2023	Jul 1, 2023	$9.04M	–
Q1 FY2023	Apr 1, 2023	-$75.59M	–
Q4 FY2022	Dec 31, 2022	$1.31M	-84.7%
Q3 FY2022	Oct 1, 2022	-$124.58M	-15092.1%
Q2 FY2022	Jul 2, 2022	-$612.00K	–
Q1 FY2022	Apr 2, 2022	-$8.97M	-130.7%
Q4 FY2021	Dec 31, 2021	$8.54M	-33.1%
Q3 FY2021	Oct 2, 2021	$831.00K	-90.3%
Q2 FY2021	Jul 3, 2021	-$3.89M	–
Q1 FY2021	Apr 3, 2021	$29.18M	+44.1%
Q4 FY2020	Dec 31, 2020	$12.76M	–
Q3 FY2020	Sep 26, 2020	$8.60M	–
Q2 FY2020	Jun 27, 2020	-$2.78M	–
Q1 FY2020	Mar 28, 2020	$20.25M	–